ClinicalTrials.gov
Cure8 trial brief
Why This Matters
People with Crohn’s disease or ulcerative colitis may have higher cardiovascular risk; this prospective study aims to measure how often major heart and vascular events occur in IBD and to find biological and clinical factors (including genetics and the microbiome) that influence that risk.
Results could help tailor cardiovascular risk assessment tools for people with IBD rather than relying on general-population scores.
Who Should Pay Attention
Adult patients with Crohn’s disease or ulcerative colitis, gastroenterology and cardiology clinicians, and researchers interested in IBD-related cardiovascular risk, genetics, microbiome, and AI-driven biomarker discovery.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment300 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
This is a trial record for a NOT_YET_RECRUITING observational study aimed at quantifying cardiovascular events (stroke, MI, AF, ischemic heart disease, cardiovascular death, arterial embolism) in adults with IBD and identifying associated risk factors using multi-omics and AI-driven analyses.
The study intends to enroll about 300 IBD patients and follow them for 2 years, collecting DNA, stool, lab tests, and clinical data; it will compare event rates with a matched cardiology cohort (CV PREVITAL). The record lists inclusion/exclusion criteria and primary outcomes but contains no results yet.
If you’re tracking links between IBD and heart disease, this study may later provide prospective data and biomarker analyses to improve risk assessment. For now, it is a planned observational protocol without outcomes or clinical recommendations.
Keep In Mind
This is a trial registration (NOT_YET_RECRUITING) describing planned methods and outcomes — it does not report study results. Interpretations should wait for completed data and peer-reviewed analysis. The record indicates use of AI and multi-omics but does not provide analytic results or validated clinical tools yet.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorIRCCS Policlinico S. Donato
Trial IDNCT07663201
Study typeObservational
Enrollment300 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 16, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Machine Learning Model Identifies Gut Biomarkers That May Help Diagnose IBD Patients
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Chinese Medical Journal review examines AI's role in inflammatory bowel - Bioengineer.org
AI tools could make objective disease assessment faster and more consistent, help detect inflammation beyond what symptoms suggest, and ultimately support more personalized treatment choices for people with Crohn’s...
Human gut flagellome profiling using FlaPro reveals TLR5-related phenotype-specific alterations in IBD.
This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...